Pfizer returned $9.5 billion directly to shareholders through dividends in 2024. Its dividend yield stands at around 6.4%, which is impressive. Those who own this Zacks Rank #3 (Hold) stock may stay invested to see how Pfizer’s new growth drivers perform. Investors with a long-term horizon...
Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison New Dividend Calculator Dividend Returns Comparison Dividend Calendar Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors Market Movers Top ...
The historical dividend returns of Pfizer, Inc., including all percentage dividend increases and decreases for PFE stock.
Pfizer Declares Second-Quarter 2025 DividendApr. 23BU Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual MeetingApr. 23BU Pfizer : Political Action Committee (PAC) Report January 2023 - December 2024Apr. 21PU
The company had just capped a record-breaking 2022with$100 billion in sales, more thanhalfof which came from its Covid vaccines and Paxlovid. Employee morale at Pfizer was relatively high at the time, some current and former workers told CNBC. The company had gone on a hiring spree and ...
something. We saw what we could do in 2020 when we rapidly developed and prepared to manufacture billions of doses of the COVID-19 vaccine, in '21 when we repeated the same with Paxlovid, and in 2022 when, with successful commercialization, we exceeded $100 billion in full year revenue....
Pfizer’s U.S. headquarters is likely to recoup the surplus through a stock buyback or dividend, observers said. However, Pfizer Korea will not be able to continue its high growth this year as the demand for Comirnaty and Paxlovid is expected to significantly decrease as Korea is transition...
We saw what we could do in 2020 when we rapidly developed and prepared to manufacture billions of doses of the COVID-19 vaccine; in '21 when we repeated the same with Paxlovid; and in 2022 when, with successful commercialization, we exceeded $100 billion in full year revenue. In 2023,...
In the second quarter, for example, we achieved year-over-year revenue growth for the first time since the fourth quarter of 2022 when our COVID revenues had reached -- had peaked. Dave will talk about this additional aspect of our financial performance as well, of course, our outlook and...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and disci...